---
search:
  boost: 3
---

# Hematopoietic Agents

This is a subcategory of Blood Formation, Coagulation, and Thrombosis Agents.

## Decision Trees

- [Hematopoietic Agents- Non-Preferred Agents - Aranesp](https://forms.office.com/Pages/ResponsePage.aspx?id=nPhjxpvvj0G9PUHkbAzgaN9UYz8EqmlIs3_TYn4TbXBUOEI3MlUwUjJHQ1IyTURBTkVZREFRRDZVQSQlQCN0PWcu){:target="_blank" rel="noopener"}

- [Hematopoietic Agents- Non-Preferred Agents - Procrit](https://forms.office.com/Pages/ResponsePage.aspx?id=nPhjxpvvj0G9PUHkbAzgaN9UYz8EqmlIs3_TYn4TbXBUNlJSMVUwTVFaWFpUNjBCVlAzTlJYTzNNRCQlQCN0PWcu){:target="_blank" rel="noopener"}

- [Hematopoietic Agents- Preferred Agents - Epogen, Mircera, Retacrit](https://forms.office.com/Pages/ResponsePage.aspx?id=nPhjxpvvj0G9PUHkbAzgaN9UYz8EqmlIs3_TYn4TbXBUMDQwWE44MTUyTlk5VEo2VEJQS1NPN1JBRyQlQCN0PWcu){:target="_blank" rel="noopener"}

## Formulary

### Preferred

| Preferred              | Generic Name | Quantity | Time (Days) |
|:-----------------------|:-------------|:--------:|:-----------:|
| Epogen <sup>PA</sup>   |              |          |             |
| Mircera <sup>PA</sup>  |              |          |             |
| Retacrit <sup>PA</sup> |              |          |             |

### Non-Preferred

| Non-Preferred | Generic Name | Quantity | Time (Days) |
|:--------------|:-------------|:--------:|:-----------:|
| Aranesp       |              |          |             |
| Procrit       |              |          |             |

## Authorizations

**Length of Authorizations**: Dependent upon diagnosis below

### Approval of epoetin alfa or darbepoetin

| Diagnosis                                                    | Hemoglobin Level | Authorization Length |
|--------------------------------------------------------------|------------------|----------------------|
| Anemia due to chronic renal failure, patient on dialysis     | ≤11              | 365 days             |
| Anemia due to chronic renal failure, patient not on dialysis | ≤10              | 365 days             |
| Chemotherapy-induced anemia                                  | ≤10              | 90 days              |
| Anemia in myelodysplastic syndrome                           | ≤11              | 180 days             |

### Approval of epoetin alfa only

| Diagnosis                                                                            | Hemoglobin Level | Authorization Length |
|--------------------------------------------------------------------------------------|------------------|----------------------|
| Autologous blood donation, patient will require blood transfusions                   | \>10 to ≤13      | 30 days              |
| Anemia of prematurity, age ≤6 months                                                 | N/A              | 42 days              |
| Anemia associated with chronic inflammatory disorders (e.g., rheumatoid arthritis)   | ≤11              | 180 days             |
| Anemia associated with ribavirin combination therapy in hepatitis C-infected patient | ≤11              | 180 days             |
| Anemia in zidovudine-treated HIV-infected patients                                   | ≤11              | 180 days             |

**All Authorizations**: Must be prescribed in accordance with FDA approved labeling

## Criteria

### Non-Preferred

Non-Preferred Criteria

- Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) **OR**
  - For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage
formulation
- Must have had an inadequate clinical response of at least ^^14 days^^ with at least ^^one preferred^^ drug
  - For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)
  - For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)

### Subsequent Authorization 

Subsequent Authorization Criteria

- Must provide documentation of patient's clinical response to treatment and ongoing safety monitoring

## Links

[Criteria](https://medicaid.ohio.gov/static/PHM/drug-coverage/20230701+UPDL+Criteria+_v1_FINAL.approved.pdf#page=14){ :target="_blank" rel="noopener"}

[Preferred Drug List](https://medicaid.ohio.gov/static/PHM/drug-coverage/20230701_UPDL_FINAL_ODM.approved.v2.pdf#page=9){ :target="_blank" rel="noopener"}

[Quantity Limit List](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230101_Ohio_Medicaid_Quantity_Document_APPROVED.pdf){ :target="_blank" rel="noopener"}
